Postmenopause Assessment Panel

The Postmenopause Assessment Panel is a blood test that measures follicle-stimulating hormone (FSH), estradiol (E2), and luteinizing hormone (LH). These hormones are involved in ovarian function and normally change as a woman transitions through menopause and enters postmenopause.

Postmenopause is generally recognized after 12 consecutive months without a menstrual period when there is no other medical or physiological explanation. In otherwise healthy women aged 45 or older who have a typical menstrual history and characteristic menopausal symptoms, laboratory confirmation is not always necessary. The diagnosis can often be made from age, symptoms, and menstrual history. Hormone measurement may be more useful when the clinical picture is unclear, menstrual history cannot be assessed reliably, or a clinician needs additional information about ovarian hormone status.

What the panel measures

• Follicle-stimulating hormone (FSH): FSH commonly increases after ovarian activity declines. An elevated level can support a postmenopausal hormonal pattern when interpreted with estradiol, age, symptoms, and medical history.
• Estradiol (E2): Estradiol is the main circulating estrogen during the reproductive years. Levels generally become lower after menopause, although individual results can vary.
• Luteinizing hormone (LH): LH is another pituitary hormone involved in ovarian function. Its level often rises after menopause and may provide additional context alongside FSH and estradiol.

When hormone measurement may be useful

The panel may be considered when postmenopausal status is uncertain, when periods cannot be used as a reliable indicator, or when symptoms and medical history do not follow the expected pattern. Examples include women who have had a hysterectomy while retaining their ovaries, women using medications that influence menstrual bleeding, or situations in which a clinician is evaluating whether hormone levels fit a postmenopausal pattern.

Some women request an assessment because they experience fatigue and low energy, poor concentration and brain fog, weight gain and difficulty losing weight, or headaches, migraines and dizziness. These concerns can occur around menopause, but they are not specific to hormonal changes. They may also be associated with thyroid disorders, anemia, sleep problems, metabolic conditions, medication effects, stress, or other health issues. The panel therefore cannot determine the cause of these symptoms on its own.

Key facts

• Panel components: FSH, estradiol, and LH
• Sample: Venous blood sample
• Preparation: No special preparation is required
• Setting: Routine outpatient blood collection
• Main purpose: Additional assessment of ovarian hormone status when clinical information alone is insufficient

How the test is performed

Step 1: Review of symptoms and medical history

Before testing, it is useful to record age, the date of the last menstrual period, previous gynecological procedures, relevant diagnoses, current symptoms, and any hormone-based medication. Hormone replacement therapy, hormonal contraception, and some other medicines may influence the measured values and their interpretation.

Step 2: Blood sample collection

A healthcare professional collects a venous blood sample, usually from a vein in the arm. The procedure generally takes only a few minutes. No special dietary preparation is required for this panel, although fasting or other instructions may apply if additional laboratory tests are performed at the same appointment.

Step 3: Laboratory measurement

The sample is tested for FSH, estradiol, and LH. Each result is reported together with the laboratory reference interval or interpretive information appropriate to the test.

Step 4: Clinical interpretation

The three results should be reviewed together rather than as isolated numbers. Age, menstrual history, symptoms, medication use, previous surgery, and the reason for testing all influence what the findings mean.

Understanding the results

A hormonal pattern with higher FSH and LH and lower estradiol can be compatible with postmenopause. However, reference intervals differ between laboratories, and no single value should be used independently to confirm menopausal status, explain symptoms, or determine treatment.

Hormone replacement therapy and other hormone-containing medications can alter FSH, LH, and estradiol levels. Results obtained during treatment may therefore require a different interpretation. Medication should not be stopped or changed before testing unless this has been specifically advised by the treating clinician.

The panel does not assess thyroid function, blood count, iron status, vitamin levels, blood glucose, liver function, or other possible explanations for nonspecific symptoms. Depending on the clinical situation, a broader laboratory assessment or medical examination may be more appropriate.

Limitations and the next step

This panel is not routinely required for every woman after the usual age of menopause. When age, menstrual history, and symptoms clearly indicate menopause, repeated hormone testing may not add useful information. Testing is most valuable when it answers a defined clinical question.

Postmenopausal bleeding, a new pelvic symptom, unexplained weight loss, severe or rapidly worsening headaches, fainting, neurological symptoms, or other significant changes should not be assessed with this panel alone. These situations require appropriate medical evaluation.

To arrange the test, send an inquiry with your age, the date of your last menstrual period if known, current symptoms, previous gynecological procedures, and a list of medications or hormone therapies. Existing laboratory findings or specialist reports may help clarify whether this panel or a broader assessment is the more appropriate next step.